Overall Neutralization of Complement Factor H by Autoantibodies in the Acute Phase of the Autoimmune Form of Atypical Hemolytic Uremic Syndrome

被引:84
作者
Blanc, Caroline [1 ,2 ,3 ]
Roumenina, Lubka T. [1 ]
Ashraf, Yahya [1 ]
Hyvaerinen, Satu
Sethi, Sidharth Kumar [4 ]
Ranchin, Bruno [5 ]
Niaudet, Patrick [6 ]
Loirat, Chantal [7 ]
Gulati, Ashima [4 ]
Bagga, Arvind [4 ]
Fridman, Wolf Herman [1 ,8 ,9 ]
Sautes-Fridman, Catherine [1 ,9 ]
Jokiranta, T. Sakari
Fremeaux-Bacchi, Veronique [1 ,8 ]
Dragon-Durey, Marie-Agnes [1 ,8 ,9 ]
机构
[1] Ctr Rech Cordeliers, INSERM, UMR Sante 872, F-75006 Paris, France
[2] Univ Paris Diderot, F-75013 Paris, France
[3] Univ Helsinki, Haartman Inst, Dept Bacteriol & Immunol, FI-00014 Helsinki, Finland
[4] All India Inst Med Sci, Dept Pediat, Div Pediat Nephrol, New Delhi 110029, India
[5] Hosp Civils Lyon, Hop Femme Mere Enfant, Serv Nephrol & Rhumatol Pediat, Ctr Reference Malad Renales Rares Nephrogones, F-69677 Bron, France
[6] Hop Necker Enfants Malad, AP HP, Serv Nephrol Pediat, F-75743 Paris, France
[7] Univ Paris Diderot, Hop Robert Debre, AP HP, Serv Nephrol, F-75019 Paris, France
[8] Hop Europeen Georges Pompidou, AP HP, Serv Immunol Biol, F-75908 Paris, France
[9] Univ Paris 05, Fac Med, F-75006 Paris, France
关键词
MUTATIONS; CLEARANCE; C3B; REGULATOR; RECEPTOR; BINDING; CFHR1; HUS;
D O I
10.4049/jimmunol.1200679
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Complement is a major innate immune surveillance system. One of its most important regulators is the plasma protein factor H (FH). FH inactivation by mutations or by autoantibodies is associated with a thrombotic microangiopathy disease, atypical hemolytic uremic syndrome. In this study, we report the characterization of blood samples from 19 anti-FH Ab-positive atypical hemolytic uremic syndrome patients collected at the acute phase of the disease. Analyses of the functional consequences and epitope mapping, using both fluid phase and solid phase approaches, were performed. The anti-FH Abs perturbed FH-mediated cell protection (100%), inhibited FH interaction with C3 (46%), and caused C3 consumption (47%). The Abs were directed against multiple FH epitopes located at the N and C termini. In all tested patients, high titers of FH-containing circulating immune complexes were detected. The circulating immune complex titers correlated with the disease stage better than did the Ab titers. Our results show that anti-FH autoantibodies induce neutralization of FH at acute phase of the disease, leading to an overall impairment of several functions of FH, extending the role of autoantibodies beyond the impairment of the direct cell surface protection. The Journal of Immunology, 2012, 189: 3528-3537.
引用
收藏
页码:3528 / 3537
页数:10
相关论文
共 32 条
[1]   Both domain 19 and domain 20 of factor H are involved in binding to complement C3b and C3d [J].
Bhattacharjee, Arnab ;
Lehtinen, Markus J. ;
Kajander, Tommi ;
Goldman, Adrian ;
Jokiranta, T. Sakari .
MOLECULAR IMMUNOLOGY, 2010, 47 (09) :1686-1691
[2]   The human complement factor H:: functional roles, genetic variations and disease associations [J].
de Córdoba, SR ;
Esparza-Gordillo, J ;
de Jorge, EG ;
Lopez-Trascasa, M ;
Sánchez-Corral, P .
MOLECULAR IMMUNOLOGY, 2004, 41 (04) :355-367
[3]   The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome [J].
Dragon-Durey, M-A ;
Blanc, C. ;
Marliot, F. ;
Loirat, C. ;
Blouin, J. ;
Sautes-Fridman, C. ;
Fridman, W. H. ;
Fremeaux-Bacchi, V. .
JOURNAL OF MEDICAL GENETICS, 2009, 46 (07) :447-450
[4]   Atypical haemolytic uraemic syndrome and mutations in complement regulator genes [J].
Dragon-Durey, MA ;
Frémeaux-Bacchi, V .
SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 2005, 27 (03) :359-374
[5]   Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome [J].
Dragon-Durey, MA ;
Loirat, C ;
Cloarec, S ;
Macher, MA ;
Blouin, J ;
Nivet, H ;
Weiss, L ;
Fridman, WH ;
Frémeaux-Bacchi, V .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (02) :555-563
[6]   Clinical Features of Anti-Factor H Autoantibody-Associated Hemolytic Uremic Syndrome [J].
Dragon-Durey, Marie-Agnes ;
Sethi, Sidharth Kumar ;
Bagga, Arvind ;
Blanc, Caroline ;
Blouin, Jacques ;
Ranchin, Bruno ;
Andre, Jean-Luc ;
Takagi, Nobuaki ;
Cheong, Hae Il ;
Hari, Pankaj ;
Le Quintrec, Moglie ;
Niaudet, Patrick ;
Loirat, Chantal ;
Fridman, Wolf Herman ;
Fremeaux-Bacchi, Veronique .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 21 (12) :2180-2187
[7]   Anti-Factor H Autoantibody-Associated Hemolytic Uremic Syndrome: Review of Literature of the Autoimmune Form of HUS [J].
Dragon-Durey, Marie-Agnes ;
Blanc, Caroline ;
Gamier, Arnaud ;
Hofer, Johannes ;
Sethi, Sidharth Kumar ;
Zimmerhackl, Lothar-Bernd .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2010, 36 (06) :633-640
[8]   Human complement factor H-related protein 2 (CFHR2) represents a novel complement regulator, which is reduced in a patient with MPGN I [J].
Eberhardt, H. E. ;
Chen, Q. ;
Zipfel, P. ;
Skerka, C. .
MOLECULAR IMMUNOLOGY, 2011, 48 (14) :1674-1674
[9]   ACQUIRED HEMOPHILIA A [J].
Franchini, Massimo ;
Lippi, Giuseppe .
ADVANCES IN CLINICAL CHEMISTRY, VOL 54, 2011, 54 :71-80
[10]   Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation [J].
Heinen, Stefan ;
Hartmann, Andrea ;
Lauer, Nadine ;
Wiehl, Ulrike ;
Dahse, Hans-Martin ;
Schirmer, Sylvia ;
Gropp, Katharina ;
Enghardt, Tina ;
Wallich, Reinhard ;
Haelbich, Steffi ;
Mihlan, Michael ;
Schloetzer-Schrehardt, Ursula ;
Zipfel, Peter F. ;
Skerka, Christine .
BLOOD, 2009, 114 (12) :2439-2447